Last reviewed · How we verify
Sensodyne Extra Whitening
Sensodyne Extra Whitening, marketed by Colgate Palmolive, holds a significant position in the oral care market. The key composition patent is set to expire in 2028, providing a competitive advantage through proprietary protection. The primary risk lies in potential increased competition post-patent expiry.
At a glance
| Generic name | Sensodyne Extra Whitening |
|---|---|
| Sponsor | Colgate Palmolive |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dentinal Hypersensitivity Reduction (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sensodyne Extra Whitening CI brief — competitive landscape report
- Sensodyne Extra Whitening updates RSS · CI watch RSS
- Colgate Palmolive portfolio CI